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symptomatic improvement while maintaining the hydropic 
ECochG pattern. At the 3-month control stage, the hydropic 
pattern resulted normalized (<0.5) in all the improved sub-
jects.  Conclusions: Although 1 month of low-pressure treat-
ment provided a positive symptomatological outcome, nor-
malization of the hydropic ECochG parameters occurred 
only at a later time. Therefore, it is possible to assume that 
endolymphatic hydrops could be concurrent with a non-
symptomatic stage of Ménière disease, and that the anti-hy-
dropic effect of the low-pressure treatment, if any, would 
present with a certain delay after its completion. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Ménière disease (MD) is a chronic, progressive, inner-
ear disorder that is characterized by sudden attacks of 
vertigo with tinnitus, ear pressure, and low-tone fluctuat-
ing hearing loss [Lopez-Escamez et al., 2016]. During the 
disease course, the auditory and vestibular functions be-
come progressively and, at times, independently affected 
regardless of the chosen treatment. Treatment options in-
clude a variety of medical approaches such as a low-salt 
diet, diuretics, steroids, calcium channel blockers, and va-
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 Abstract 
 Objective: To identify eventual correlations between the ef-
fect of low-pressure treatment and endolymphatic hydrops 
in Ménière patients.  Material and Methods: The study group 
consisted of subjects affected by definite Ménière disease 
(2015) and a severe degree of disability, who received a ven-
tilation tube with or without a low-pressure treatment be-
fore undergoing a surgical procedure (vestibular neurecto-
my). After the placement of the ventilation tube, the subjects 
were either left alone with the tube or received 1 month of 
self-administered low-pressure therapy with a portable de-
vice. In all subjects, an electrocochleography (ECochG) was 
performed and specific questionnaires – Dizziness Handicap 
Inventory (DHI) and Functional Scale Level (FSL) – were com-
pleted before starting either arm of treatment, at the end of 
treatment, and then 3 and 6 months later.  Results: All se-
lected subjects presented with an ECochG pattern that was 
indicative of endolymphatic hydrops before starting either 
treatment. At the end of pressure treatment, 80% showed 
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sodilators. Medical therapy is generally reported to pro-
vide disease control in nearly 70% of MD patients [Semaan 
and Megerian, 2011].
 In those MD patients who are refractory to this pre-
liminary approach, the intra-tympanic administration of 
different drugs (gentamicin, steroids) is used worldwide 
before considering a possible surgical solution. As well as 
intra-tympanic therapy, since the late 1990s a controlled, 
low-pressure treatment is also available through a porta-
ble device, built on the ground of a series of experimental 
studies that support its positive role for normalization of 
the inner ear fluid volumes [Tjernstrom, 1977; Densert et 
al., 1986]. This treatment may be considered conservative 
for the absence of cochlear damage as well as being non-
invasive, only requiring the placement of a short-term 
ventilation tube (VT) for the direct transmission of pres-
sure pulses through the external auditory canal into the 
middle ear. Despite not being very popular, several clini-
cal reports have highlighted, in randomized trials, the 
positive role of such a device in selected cases of MD 
[Thomsen et al., 2005; Gürkov et al., 2012]. Fifteen years 
of continuous use at our centre has allowed us to confirm 
its positive role for the treatment of MD in patients who 
do not respond to initial medical therapies and who 
would thus be candidates for a surgical solution owing to 
the recurrence of disabling vertigo spells [Barbara et al., 
2001, 2007]. A recent meta-analysis has reported that its 
use provided complete remission of the disease in 52% of 
the treated patients and substantial remission in 34% of 
them, with an overall positive effect in nearly 80% of cas-
es [Zhang et al., 2016]. Nevertheless, the mechanism that 
underlies this positive effect remains unknown.
 The present study was designed to shed some light on 
the possible relationships between local pressure treat-
ment and endolymphatic hydrops, which is still consid-
ered the major landmark in MD and has been assessed by 
serial electrocochleographic (ECochG) recordings.
 Material and Methods 
 Twenty consecutive patients (14 males and 6 females, mean age 
56.3 years, range 41–83 years), who presented in the last 2 years 
with a clinical picture of definite MD, were included in this study. 
All patients had previously undergone unsuccessful medical ther-
apy and were still complaining of invalidating and frequent vertigo 
spells (class D, American Academy of Otolaryngology-Head and 
Neck Surgery [AAO-HNS], 1995), so as to prompt the adoption of 
other invasive or destructive treatment approaches such as intra-
tympanic gentamicin, sac surgery, or vestibular neurectomy. Ac-
cording to our pressure protocol [Barbara et al., 2001], they all first 
underwent trans-tympanic insertion of a VT. After 1 week, they 
were then randomized in one group that was left with the VT only 
(10 cases) and another group that was given 1 month of pressure 
therapy with the Meniett ® device (Medtronic ENT, Jacksonville, 
FL, USA) (10 cases).
 All subjects received a hearing evaluation that consisted of the 
assessment of their pure tone audiogram (PTA) and, more specifi-
cally, the mean threshold at 4 adjacent frequencies – 500, 1,000, 
2,000, and 4,000 Hz (PTA4) – that allowed the categorization of the 
patients, in accordance with the AAO-HNS criteria for hearing, 
into class I (<25 dB), II (26–50 dB), III (51–70 dB), and IV (>71 dB).
 The first step of the protocol consisted of placing a trans-
tympanic short-term VT under local anaesthesia. Soon after, an 
ECochG was performed inside an electrically and acoustically 
shielded room, using standard Otometrics equipment (ICS Chartr 
EP 200). With the patient in a supine position, a silver wire elec-
trode, sheathed by a polyethylene tube embedded in hydrogel (Lil-
ly TM-Wick electrode; Intelligent Hearing Systems, Miami, FL, 
USA), was positioned through the VT. The acoustic stimulation 
consisted of alternating polarity clicks (99-dB normal hearing lev-
el) that were presented at a rate of 7.1/s, while the responses were 
averaged for 600 stimuli/s. The click-evoked summating potential 
(SP) amplitude was defined as the difference between the pre-stim-
ulus baseline level and the first deflection. The action potential 
(AP) amplitude was measured from the baseline level to the first 
negative peak. After identifying both points, the SP/AP ratio was 
calculated. In this study, an SP/AP ratio of 0.50 or greater was con-
sidered indicative of a hydropic condition [Filipo et al., 1997]. Ad-
ditionally, all subjects were asked to preliminarily complete the 
Dizziness Handicap Inventory (DHI) questionnaire for assessing 
their perceived disability, which allowed for investigation of the 
functional, emotional, and physical aspects; the higher the score 
(Q), the greater the perceived disability due to dizziness [Jacobson 
and Newman, 1990]. Vertigo control was also assessed according 
to the 1995 AAO-HNS classification, ranging from complete 
(grade A) to poor (grade D) control [Monsell, 1995], and by the 
Functional Scale Level (FSL).
 The Meniett ® device consists of a low-pressure generator that 
delivers 0.6-s pressure pulses at 6 Hz within the range of 0–20 cm 
H 2 O to the ear canal. According to our protocol, each automati-
cally set treatment cycle consisted of 3 sessions of 5 min each, in-
cluding 1 min of pressure pulses and 40 s of pause. These daily 
sessions were prescribed to be performed during an entire month, 
starting 1 week after VT placement.
 For the present protocol, the following 4 assessment times (T) 
were identified: the beginning Meniett treatment (T0, 1 week after 
VT placement); the end of Meniett treatment (T1, 30 days later); 
follow-up after 3 months from T0 (T2); and follow-up after 6 
months from T0 (T3). The same times were also considered for 
assessing those subjects who only received the VT.
 All the subjects signed an informed consent form, and the study 
was performed in accordance with the principles of the Declara-
tion of Helsinki.
 Statistical Analysis 
 Continuous data were summarized by mean and SD, while cat-
egorical data were summarized with count and percentage. Cate-
gorical variables were compared using the χ 2 or Fisher exact tests. 
The  p values are 2-sided; a  p value  ≤ 0.05 was considered statisti-










































 The mean disease duration before entering the study 
was 3.2 years (range from 6 months to 25 years), and fol-
low-up included up to 6 months after the end of treat-
ment. During the first phase of the study (between T0 and 
T1), 2 subjects who were randomized for the VT only 
group asked to withdraw from it due to the persistence of 
debilitating symptoms and moved to the Meniett treat-
ment (and group), which was in the subjects’ opinion 
considered a therapeutic implementation. For ethical rea-
sons their request was granted, although this produced an 
uneven number of subjects distributed in the 2 study 
groups (12 for the Meniett group vs. 8 for the VT group).
 T0 
 An ECochG hydropic pattern was present in all sub-
jects before they started the study. The mean SP/AP ratio 
value was 0.7 in the VT group (range 0.62–0.82) and 0.7 
in the Meniett group (range 0.53–0.9).
 All the patients described a debilitating disease and 
were therefore classified as belonging to class D, with a 
mean DHI score of 81.75 (range 66–92) for the VT group 
and 82.8 (range 64–100) for the Meniett group.
 The mean PTA was 59.7 dB (min. 38.7; max. 71.2) in 
the VT group and 62.6 dB (min. 26.2 dB; max. 82.5 dB) in 
the Meniett group. On the ground of the mentioned hear-
ing thresholds, the patients were classified as stage I (no 
patient in either group), stage II (1 VT, 2 Meniett), stage 
III (4 VT, 7 Meniett), and stage IV (3 VT, 3 Meniett) ( Ta-
ble 1 ).
 T1 
 At 1 month from treatment, an ECochG hydropic pat-
tern was present in 9 patients (75%) in the Meniett group 
and in all VT subjects ( Table 2 ). In 3 patients in the Me-
niett group, the ECochG pattern appeared to decrease to 
a normal value range of 0.48, 0.40, and 0.42, respectively. 
From a symptomatic point of view, 7 subjects (58.4%) in 
the Meniett group and 2 VT subjects (25%) had an im-
provement that was framed under class A or B ( Table 2 ), 
as well as a mild DHI score (<30). The mean PTA in the 
Meniett group was 59.6 dB (min. 16.2 dB; max. 82.5 dB), 
dropping by 3 dB; in the VT group, the mean PTA was 
58.4 dB (min. 41.2; max. 73.7) with a drop of 1.3 dB.
 T2 
 Three months after T0, a hydropic SP/AP ratio was 
observed in 2 of the Meniett patients (16.7%) and in 7 VT 
patients (87.5%) ( Table 2 ). All hydropic subjects in both 
groups had a DHI score >50, and they were still framed 
under class D. The mean PTA was 60.5 dB (min. 30 dB; 
 Table 1.  Demographics of the study sample
Meniett VT
Mean age, years 56.9 55.3
Male/female 7/5 7/1
Mean ECochG SP/AP 0.7 0.7
AAO-HNS class D D
DHI 82.8 81.7
Mean PTA4 62.6 59.7
 VT, ventilation tube; ECochG, electrocochleography; SP, sum-
mating potential; AP, action potential; AAO-HNS, American 
Academy of Otolaryngology-Head and Neck Surgery; DHI, Dizzi-
ness Handicap Inventory; PTA4, pure tone average at 500, 1,000, 
2,000, and 4,000 Hz.
 Table 2.  ECochG findings at the different follow-up times taken into consideration: before treatment (T0) and after 1 (T1), 3 (T2), and 
6 months (T3) in the Meniett and VT groups
T0 T1 T2  T3
Meniett VT Meniett VT Meniett VT Me niett VTa
SP/AP >0.5 (hydrops) 12 (100) 8 (100) 9 (75) 8 (100) 2 (16.7) 7 (87.5) 2 (16.7) 4 (80)
SP/AP <0.5 (no
hydrops)
0 (0) 0 (0) 3 (25) 0 (0) 10 (83.3) 1 (12.5) 10 (83.3) 1 (20)
 Values are n (%). ECochG, electrocochleography; VT, ventilation tube; SP/AP, difference between summating potential and action 
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max. 82.5 dB) in the Meniett group (drop of 2.1 dB) and 
59.5 dB (min. 43.7, max. 72.5) in the VT group (drop of 
0.2 dB).
 T3 
 Six months after T0, the 2 patients in the Meniett 
group who lacked symptom improvement, and instead 
experienced persistence of the hydropic ECochG pattern, 
were considered for vestibular neurectomy. Among the 
VT group, 3 subjects left the protocol after 3 months. 
Four out of the 5 remaining subjects continued to have a 
hydropic pattern with a disabling condition, while the 
non-hydropic VT subjects had symptom remission.
 A significant difference in the hydropic pattern be-
tween the 2 study groups was found with the Fisher exact 
test at 3 months ( p = 0.005) and 6 months ( p = 0.028).
 Audiometric Results 
 The mean PTA at the different follow-up steps is 
shown in  Table 3 . No differences were found in PTA be-
fore and 1, 3, and 6 months after Meniett treatment and 
in the VT group (T0-T1-T2-T3) [Thomsen et al., 2005]. 
No statistical difference in the pre- and post-treatment 
hearing thresholds was evidenced (Mann-Whitney U test 
and Friedman test).
 DHI Results 
 The following 3 categories of severity could be distin-
guished: severe (score of 61–100), moderate (31–60), and 
mild (0–30). The single scores for each follow-up time are 
shown in  Table 4 . One month after treatment, 7 patients 
(58.4%) reported a DHI improvement without normal-
ization of the SP/AP ratio. At 3 and 6 months after treat-
ment, a significant improvement at DHI corresponded to 
a remarkable reduction, with normalization, of the SP/AP 
ratio values ( Table 4 ). Significant differences were found 
between Meniett and VT when testing the DHI at T2 (3 
months after treatment) ( p = 0.001) and T3 (6 months 
after treatment) ( p = 0.005).
 Discussion 
 Endolymphatic hydrops is considered the pathological 
finding of several inner ear disorders, including MD 
[Hallpike and Cairns, 1980]; as a result, its post-mortem 
finding allows defining MD as certain [Monsell, 1995]. 
Although promising reports have recently highlighted 
the possible role of magnetic resonance (MRI) techniques 
in obtaining a clear depiction of endolymphatic hydrops 
in living subjects [Wu et al., 2016], ECochG has long been 
used for the same purpose taking into consideration the 
increased ratio between the SP and AP after stimulation 
with alternating polarity clicks [Gibson et al., 1977]. In 
particular, the elevation of the SP/AP ratio has been con-
sidered as proof for endolymphatic hydrops and ex-
plained by the displacement of the basilar membrane to-
wards the scala tympani in response to endolymphatic 
overload [Eggermont, 1974].
 To the best of our knowledge, no previous reports have 
been published on the possible relationships between Me-
niett treatment and endolymphatic hydrops, either based 
on imaging or electrophysiological techniques. There-
 Table 3.  Mean PTA at the different follow-up times: before treat-
ment (T0) and after 1 (T1), 3 (T2), and 6 months (T3) in the Me-
niett and VT groups
T0 T1 T2 T3
Meniett group 62.6 59.6 60.5 62.7
VT group 59.7 58.4 59.5 58.1
 PTA, pure tone average; VT, ventilation tube.
 Table 4.  DHI findings before treatment (T0) and after 1 (T1), 3 (T2), and 6 months (T3) in the Meniett and VT groups
T0 T1 T2  T3
Meniett VT Meniett VT Meniett VT Me niett VTa
Severe 12 (100) 8 (100) 5 (41.6) 6 (75) 1 (8.4) 1 (75) 1 (8.4) 3 (60)
Moderate 0 (0) 0 (0) 5 (41.6) 2 (25) 1 (8.4) 1 (12.5) 1 (8.4) 1 (20)
Mild 0 (0) 0 (0) 2 (16.8) 0 (0) 10 (83.2) 1 (12.5) 10 (83.2) 1 (20)








































fore, the present study was designed with this aim, and 
endolymphatic hydrops was assessed with ECochG. Al-
though controversial reports have been published on the 
reliability of click-evoked ECochG [Gürkov et al., 2012], 
the use of this setting in the present study allowed for con-
firmation of our patients as classical MD subjects. In all 
of the patients, according to the protocol, pressure treat-
ment was offered before proposing a surgical option in 
light of their disability and the recurrence of severe ver-
tigo spells. In fact, it is our opinion that vertigo control 
should be the only reason for applying local pressure 
treatment, and that its eventual influence on the other 
MD symptoms (hearing loss, fullness, and tinnitus), al-
though possible, should never represent its primary indi-
cation. In fact, when the main aim is resolution of non-
vertigo symptoms, pressure treatment is likely to fail. Our 
suspicion, instead, is that its inappropriate indication, fol-
lowed by failure, has contributed to raise some scepticism 
around its use. Another observation is related to the role 
of the presence of a VT, which has also been reported to 
provide a successful outcome in MD subjects [Montan-
don et al., 1988]. Consequently, for the present study it 
has been decided to include, via randomization, a group 
of Ménière subjects in whom VT insertion was not fol-
lowed by pressure treatment, with the aim of ruling out 
any possible favourable role played by passive ventilation 
of a VT on MD. In this regard, the exit from the VT group 
of 2 subjects, who specifically asked to be included in the 
Meniett group due to aggravation of symptoms after in-
sertion of the VT, consequently created an uneven distri-
bution of the sample within the study group. Despite this 
methodological limitation, the findings evidenced in all 
the study phases, including the final follow-up observa-
tion time (T3), would in our opinion allow drawing some 
interesting remarks that are worth being discussed.
 Once properly classified into class C or D, and selected 
for pressure treatment, it seemed interesting to determine 
whether endolymphatic hydrops was always underlying 
the symptomatic stage. To obtain this information, the 
ECochG examination was applied and used as a tool for 
monitoring the disease course immediately before and af-
ter treatment. All MD subjects included in this study pre-
sented with a pathological ECochG pattern that was com-
patible with endolymphatic hydrops. This first finding 
supports the validity of the sample selection, since in this 
preliminary phase of the study the clinical picture matched 
the electrophysiological finding, which is in favour of the 
presence of endolymphatic hydrops. However, after the 
first follow-up (T1), which was scheduled at the end of 
treatment, some subjects showed a mismatch between 
their symptoms and the electrophysiological findings. In 
fact, at stage T1, an abnormal, hydropic ECochG pattern 
was still present in a considerable number of subjects 
(75%), although the majority of them (nearly 60%) were 
already reporting a symptomatic improvement, shown by 
the drastic decrease in the DHI score and a shift of 1 or 2 
classes . When looking at the results of stages T2 and T3, 
the symptomatic improvement that was found in 86% of 
the entire pressure-treated group corresponded to a nor-
malization of the ECochG pattern, with an SP/AP ratio 
<0.5, while the subjects of the same group who showed no 
improvement (2 patients, equivalent to 12% of the group) 
still presented a hydropic ECochG pattern with persis-
tence of a high DHI score and the same class of disease. 
This correlation between symptomatic control and the 
persistence of hydrops, which was also found in all sub-
jects included in the VT group in the present study, seems 
extremely significant and emphasizes the importance of 
routine application of any diagnostic tool that would en-
able the acquisition of evidence of endolymphatic hy-
drops (ECochG or enhanced MRI). This concept has also 
been recently pointed out when analysing the negative 
outcome in subjects who underwent endolymphatic sac 
surgery [Liu et al, 2016].
 Based on these findings, the active pressure treatment 
has been shown to be successful in the majority of the 
treated patients, which is in agreement with previously 
published studies; however, these studies lacked an expla-
nation of the modality of action of the pressure device 
[Gürkov et al., 2012; Van Sonsbeek et al., 2015]. From the 
data collected in the present study, it would seem that 
Meniett therapy displays a positive influence on the dis-
tended endolymphatic space, as evidenced by the normal-
ization of the SP/AP ratio in the responding subjects. In 
this regard, however, the ECochG pattern of behaviour 
seems controversial. In fact, the hydropic pattern re-
mained stable at stage T1 (after 1 month of treatment) in 
the majority of subjects who were already showing a 
symptomatic improvement. Only 3 months later (stage 
T2) did the ECochG normalization correspond to the 
DHI decrease. One may argue that, from a symptomato-
logical point of view, this finding could represent the ef-
fect of the natural course of the disease, but the evidence 
gathered in the control group seems to rule out this pos-
sibility. Hence, a positive outcome for the pressure treat-
ment could also positively influence the inner ear fluid 
volume, but it may have a delayed effect that escapes in 
the first ECochG assessment at 1 month, while appearing 
and remaining stable at the 3-month control. This de-
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ferring to the clinical expression of inner ear pathologies, 
basing on the histological finding of endolymphatic hy-
drops [Schuknecht, 1978]. It would therefore be plausible 
to speculate that the presence of partitions and valves 
within the membranous labyrinth could contribute to a 
sectorial behaviour of the different labyrinthine compart-
ments when elicited by a hydropic condition, so that the 
pressure treatment would first positively influence the 
vestibular part, as shown by the early symptomatological 
improvement, and only at a later time the cochlear part, 
as assessed by the delayed electrophysiological findings. 
These considerations remain at a merely speculative level 
and obviously need to be substantiated by further conclu-
sive studies.
 The Meniett treatment has, in our hands, confirmed 
its positive value as a conservative treatment that can be 
offered to MD subjects who are refractory to medical 
therapy and for whom a destructive procedure, such as 
intra-tympanic gentamycin or vestibular neurectomy, 
could be indicated. Unlike gentamycin treatment, which 
may induce hearing deterioration, this pressure treat-
ment is a true conservative option that does not affect 
hearing and is nearly devoid of possible complications, 
except for the need to tubulate the eardrum, which can 
result in permanent perforation. However, such a nega-
tive outcome has never been observed in over 100 subjects 
treated at our centre. At the same time, the presence of 
the VT tube was helpful in the present study because it 
allowed us to serially perform trans-tympanic ECochG 
with an exploration needle passing inside the lumen, 
therefore minimizing the patient’s discomfort in this po-
tentially invasive diagnostic procedure.
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